(Q37424635)

20 August 2017

Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis (English)

1 reference

20 August 2017

0 references

1 reference

Adedigbo A Fasanmade

1

1 reference

20 August 2017

Omoniyi J Adedokun

2

1 reference

20 August 2017

Joyce Ford

3

1 reference

20 August 2017

Danika Hernandez

4

1 reference

20 August 2017

Jewel Johanns

5

1 reference

20 August 2017

Chuanpu Hu

6

1 reference

20 August 2017

Hugh M Davis

7

1 reference

20 August 2017

Honghui Zhou

8

1 reference

20 August 2017

16 September 2009

1 reference

European Journal of Clinical Pharmacology

20 August 2017

1 reference

20 August 2017

65

1 reference

20 August 2017

12

1 reference

20 August 2017

1211-1228

1 reference

https://scigraph.springernature.com/pub.10.1007/s00228-009-0718-4

20 August 2017

0 references

cites work

Tumor necrosis factor antagonist mechanisms of action: a comprehensive review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2778780

Clinical pharmacokinetics and use of infliximab

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2778780

Diagnosing model diagnostics

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2778780

Infliximab for induction and maintenance therapy for ulcerative colitis

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2778780

Infliximab: a review of its use in Crohn's disease and rheumatoid arthritis

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2778780

Pharmacokinetic considerations in the treatment of inflammatory bowel disease

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2778780

Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2778780

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2778780

Prediction of creatinine clearance from serum creatinine

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2778780

Population pharmacokinetics of infliximab in patients with ankylosing spondylitis

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2778780

Kinetics of FcRn-mediated recycling of IgG and albumin in human: pathophysiology and therapeutic implications using a simplified mechanism-based model

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2778780

Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2778780

Stability and performance of a population pharmacokinetic model

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2778780

Infliximab pharmacokinetics in inflammatory bowel disease patients.

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2778780

Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2778780

The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial

2 September 2018

1 reference

12 December 2020

Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-alpha monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris

1 reference

12 December 2020

Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study

1 reference

12 December 2020

Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM

1 reference

12 December 2020

Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial

1 reference

12 December 2020

Population pharmacokinetic modeling of subcutaneously administered etanercept in patients with psoriasis

1 reference

12 December 2020

10.1007/S00228-009-0718-4

Identifiers

DOI

1 reference

release_f3z2urv7ujh5hjb4ukinqrqnzi

20 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/f3z2urv7ujh5hjb4ukinqrqnzi

24 November 2022

mapped directly with Wikidata item

1 reference

20 August 2017

PubMed publication ID

19756557

1 reference